|
|
Article: Mentor Capital Cancer Immunotherapy Index Improves at a 320% Annualized Rate for Quarter.
- Article from:
- Cancer Weekly
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
The Cancer Immunotherapy Index of ten leading cancer immunotherapy stocks has increased 80% during its first three months of measurement. The CI Index as a whole trades for 10% of estimated future revenues. The implied 1,000% possible increase is consistent with the 1,000% share price increase of the CI Index company furthest along in FDA trials, Dendreon (NASDAQ:DNDN). The share price increase followed Dendreon's positive Phase III prostate cancer immunotherapy results during March 2009 (see also Mentor Capital, Inc.).
Two companies have lead the CI Index during the quarter in both growth and potential growth. ImmunoCellular Therapeutics, Inc. (IMUC.OB) was 1st ...
Related newspaper, magazine, and journal articles:
|
|
Article: Mentor Capital, Inc. Initiates Trading at $1.05/sh ...
Business Wire;
September 5, 2008 ;
700+ words
...SAN DIEGO -- Mentor Capital, Inc. (Pink Sheets: MNTR ... receivables from its investments. Mentor Capital, Inc. is a rapidly evolving zero ... hedge funds and private companies. Mentor Capital targets firms that are generally ...
|
|